Global Cord Blood Corporation (CO) Comparison with companies in other sectors?

Global Cord Blood Corporation has a share price of 133.91M. You can analyze Global Cord Blood Corporation (CO) competitors across different market sectors through stock heatmaps.

What are CO's NET and operating margins?

Global Cord Blood Corporation (CO) operating margin is around 0.49, and net profit margin is approximately 0.40 as of the latest reports.

In what way does CO's earnings per share (EPS) trend reflect its financial momentum?

Global Cord Blood Corporation (CO) EPS is 0.59 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Global Cord Blood Corporation is 5.06, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Global Cord Blood Corporation?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Global Cord Blood Corporation like P/E which is 5.19, P/B which is 0.53, and PEG which is 0.007. Compare them with sector averages to evaluate if the stock is priced fairly.

Global Cord Blood Corporation

CO•NYSE

Healthcare

Medical - Diagnostics & Research

$2.99

$0.77(34.58%)

Fundamental Analysis of Global Cord Blood Corporation (CO)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.59

P/E Ratio

5.06

ROE

0.11%

Net Margin

0.40%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$400.08M

Shares OutstandingTotal number of shares issued

$133.91M

Book Value/ShareNet worth per share

$40.19

Revenue/ShareAnnual revenue per share

$10.23

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.59

Net MarginNet income as percentage of revenue

40.30%

Operating MarginOperating income as percentage of revenue

48.97%

ROEReturn on shareholders' equity

10.82%

ROAReturn on total assets

5.87%

ROCEReturn on capital employed

7.72%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$4.89

Cash/ShareCash and equivalents per share

$54.80

FCF YieldFree cash flow as percentage of market cap

20.71%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for COFinancial Ratios Analysis details for CO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for COSector Benchmarking details for CO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Global Cord Blood Corporation Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Global Cord Blood Corporation. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Global Cord Blood Corporation's unique business strengths and challenges.

Key Financial Metrics for Global Cord Blood Corporation

For Global Cord Blood Corporation, essential financial indicators include EPS 0.59, PE 5.06, and ROE 0.11. These key ratios reveal insights into Global Cord Blood Corporation's profitability, valuation, and operational health. Understanding these metrics enables you to compare Global Cord Blood Corporation with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Global Cord Blood Corporation

Metrics like Net Margin 40.30% and ROA 5.87% shed light on how well Global Cord Blood Corporation is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Global Cord Blood Corporation can sustain its operations and continue growing in the future.

Valuation and Market Position of Global Cord Blood Corporation

Using ratios such as P/B Ratio 0.53 and PEG Ratio 0.007, investors can assess whether Global Cord Blood Corporation is appropriately valued based on its financials and growth potential. These figures, combined with Global Cord Blood Corporation's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Global Cord Blood Corporation

Financial health indicators, such as Debt/Equity Ratio 0.00 and Cash Flow $4.89, provide a snapshot of Global Cord Blood Corporation's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Global Cord Blood Corporation, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Global Cord Blood Corporation

Investing in Global Cord Blood Corporation based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Global Cord Blood Corporation focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;